[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336576-105":59,"doc-detail-336576-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","understanding-homologous-recombination-repair-deficiency-in-biliary-tract-cancers-clinical-implications-and-correlation-with-platinum-sensitivity","Understanding homologous recombination repair deﬁciency in biliary tract cancers - clinical implications and correlation with platinum sensitivity","","Biliary tract cancers (BTCs) show high mortality and marked heterogeneity across clinical and molecular features. This study retrospectively analyzed 256 BTC patients treated from 2016 to 2023 across multiple Austrian and German centers, using comprehensive genomic profiling to assess homologous recombination repair (HRR) status and relate HRR gene mutations (HRRm) to outcomes after platinum-based chemotherapy. Sixty-seven patients (27.5%) had HRRm. HRRm status suggested a potential overall survival advantage in the first-line platinum setting, with additional observations of interactions with later, molecular-informed treatment strategies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/understanding-homologous-recombination-repair-deficiency-in-biliary-tract-cancers-clinical-implications-and-correlation-with-platinum-sensitivity/336576/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/understanding-homologous-recombination-repair-deficiency-in-biliary-tract-cancers-clinical-implications-and-correlation-with-platinum-sensitivity/336576.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main objective of this study on biliary tract cancers?","Question",{"text":113,"@type":114},"To molecularly characterize BTC patients in a real-world setting, focusing on genomic alterations in homologous recombination repair (HRR) genes and how these relate to clinical outcomes after platinum-based chemotherapy.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How many patients had HRR gene mutations (HRRm) and what was the proportion?",{"text":118,"@type":114},"Out of 256 patients, 67 (27.5%) exhibited HRR gene mutations (HRRm).",{"name":120,"@type":111,"acceptedAnswer":121},"Did HRRm status improve outcomes with platinum-based first-line chemotherapy?",{"text":122,"@type":114},"The results showed a potential advantage in overall survival after platinum-based first-line chemotherapy for patients with HRRm, while significance did not persist in multivariate analysis.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},336576,1790171492,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","ORIGINAL RESEARCH  \nUnderstanding homologous recombination repair deﬁciency in biliary tract cancers: clinical implications and correlation with platinum sensitivity  \nI.-A. Mavroeidi1, 2, 3, J. Burghofer4, S. Kalbourtzis5, H. Taghizadeh6, G. Webersinke4, G. Piringer7, 8, S. Kasper1, 2, G. Schreil9,  \nS. T. Liffers2, 3, A. Reichinger10, P. Kirchweger8, 11 , 12, S. Heibl13, R. Hamacher1, 2, C. A. Schmitt7, 8, M. Schuler1, 2, 14,  \nG. W. Prager15, D. Kersting2, 16, J. Treckmann2, 17, H.-U. Schildhaus5, 18, H. Rumpold8 , 12, J. T. Siveke1, 2, 3 􀀁 & B. Doleschal8 , 10􀀁 1Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen; 2Division of Solid Tumor Translational Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen; 3Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany; 4Laboratory for Molecular Genetic Diagnostics, Ordensklinikum Linz, Linz, Austria; 5Institute of Pathology, West German Cancer Center, University Hospital Essen, Essen, Germany; 6Department of Internal Medicine, Universitätsklinikum St. Pölten, St. Pölten; 7Department of Oncology and Hematology, Kepler University Hospital, Linz; 8Medical Faculty, Johannes Kepler University Linz, Linz; 9Department of Internal Medicine, State Hospital Pyhrn Eisenwurzen, Steyr; 10Department of Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology, and Medical Oncology, Ordensklinikum Linz, Linz; 11Department of General and Visceral Surgery, Ordensklinikum Linz, Linz; 12Gastrointestinal Cancer Center, Ordensklinikum Linz, Linz; 13Department of Internal Medicine IV, Hospital Wels-Grieskirchen, Wels, Austria; 14National Center for Tumor Diseases (NCT) West, Campus Essen, Essen, Germany; 15Department of Medicine I, Division of Oncology, Medical University Vienna, Vienna, Austria; 16Department of Nuclear Medicine, University Hospital Essen, Essen; 17Department of General, Visceral and Transplantation Surgery, University Hospital Essen, Essen; 18Discovery Life Sciences Biomarker GmbH und Pathologie Nordhessen, Kassel, Germany  \nAvailable online xxx  \nBackground: Biliary tract cancers (BTCs) exhibit high mortality rates and signiﬁcant heterogeneity in both clinical and molecular characteristics. This study aims to molecularly characterize a cohort of patients with BTC, with a speciﬁc focus on genomic alterations within homologous recombination repair (HRR) genes in a real-world setting.  \nPatients and methods: We carried out a retrospective analysis on 256 patients with BTC treated at ﬁve Austrian centersand one German comprehensive cancer center between 2016 and 2023 utilizing comprehensive genomic proﬁling platforms to assess HRR status and its correlation with clinical outcomes after platinum-based chemotherapy. Results: A total of 67 patients (27 .5%) exhibited HRR gene mutations (HRRm), with the most common pathogenic alterations in BAP1 (9%), ARID1A (7 .8%), and ATM (6 . 1%) . Time to failure of the ﬁrst-line strategy (TFS) between patients with HRRm and non-HRRm treated with platinum agents was 7.9 and 6.7 months, respectively [hazard ratio (HR) 0 .89; P ¼ 0.49] . The overall survival (OS) estimates at 6, 18, and 24 months were 82%, 45%, and 39% in the HRRm group (median 16.01 months) and 81%, 42%, and 22% in the HRR group (median 15.68 months), respectively (Fleming-Harrington test P ¼ 0.0004; log-rank P ¼ 0.022) . Signiﬁcance did not persist in the multivariate analysis (HR 0 .72; 95% conﬁdence interval 0 .489-1.059; P ¼ 0.095) . An interaction between HRRm status and molecular-informed therapeutic strategies in later lines was noted. In the second-line treatment, OS following an irinotecan-based regimen was comparable to re-exposure to platinum-based agents (12.36 versus 10.13 months; HR 0 .92; P ¼ 0.85) . No better outcome was noted for patients with HRRm versus patients with no","cbCaiipqI0ifmTfS","https://ap.wps.com/l/cbCaiipqI0ifmTfS","pdf",561664,"English","# Background\n# Patients and methods\n## Cohort and genomic profiling\n## Outcomes after platinum-based chemotherapy\n# Conclusions\n# Key words","[{\"question\":\"What was the main objective of this study on biliary tract cancers?\",\"answer\":\"To molecularly characterize BTC patients in a real-world setting, focusing on genomic alterations in homologous recombination repair (HRR) genes and how these relate to clinical outcomes after platinum-based chemotherapy.\"},{\"question\":\"How many patients had HRR gene mutations (HRRm) and what was the proportion?\",\"answer\":\"Out of 256 patients, 67 (27.5%) exhibited HRR gene mutations (HRRm).\"},{\"question\":\"Did HRRm status improve outcomes with platinum-based first-line chemotherapy?\",\"answer\":\"The results showed a potential advantage in overall survival after platinum-based first-line chemotherapy for patients with HRRm, while significance did not persist in multivariate analysis.\"}]","Understanding homologous recombination repair deﬁciency in biliary tract cancers - clinical implications and correlation with platinum sensitivity | PDF",1790015686,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ed9798d6d226743797a70c5c707e137a.webp",983,1269,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd3d355f45fb666706510e6b7167e0a9.webp",982,1268,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fcbe5f664480a5fec618604b5f6cde3e.webp",981,1266,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e1c06d46b41903339927dc02b1baf25d.webp",980,1265]